Do you want to read an article? Please log in or register.
Treatment to Target in Psoriatic Arthritis with Apremilast: Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
Psoriatic Arthritis
Related content
Further Publications Dermatology
Effect of Baseline Disease Severity on Achievement of Treatment Target With Apremilast: Results From a Pooled Analysis
J Eur Acad Dermatol Venereol
Reich K, Mrowietz U, Menter A, Griffiths CEM, Bagel J, Strober B, Nunez Gomez N, Shi R, Guerette B, Lebwohl M
doi: 10.1111/jdv.17520
Psoriatic Arthritis
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis
Arthritis Rheumatol.
Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS
doi: 10.1002/art.40391.
Psoriatic Arthritis
Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
Rheumatology (Oxford).
Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC
doi: 10.1093/rheumatology/key417.
COMMENTED
Psoriatic Arthritis
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1016/S0140-6736(20)30265-8.
Psoriatic Arthritis
Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?
Ann Rheum Dis.
Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML
doi: 10.1136/annrheumdis-2018-213463.
Psoriatic Arthritis
Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
Rheumatology (Oxford).
Coates LC, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman AJ,
Nantel F
doi: 10.1093/rheumatology/key359.
Psoriatic Arthritis
Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate
Ann Rheum Dis.
van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D
doi: 10.1136/annrheumdis-
Psoriatic Arthritis
Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial
Arthritis Res Ther.
Mease P, Husni ME, Kafka S, Chakravarty SD, Harrison DD, Lo KH, Xu S, Hsia EC, Kavanaugh A
doi: 10.1186/s13075-020-2126-1.
Rheumatoid Arthritis
Patient- and Rheumatologist- Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis
Arthritis Care Res (Hoboken).
Owensby JK, Chen L, O'Beirne R, Ruderman E, Harrold LR, Melnick JA, Safford MM, Curtis JR, Danila MI
doi: 10.1002/acr.23907.